Silk fibroin based carrier system for delivery of fibrinogen and thrombin as coagulant supplements
Corresponding Author
Andreas H. Teuschl
Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, 02155 USA
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Correspondence to: A.H. Teuschl; University of Applied Sciences Technikum Wien, Department of Biochemical Engineering, Wien, Austria; e-mail: [email protected]Search for more papers by this authorJohannes Zipperle
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA Research Center, Vienna, Austria
Search for more papers by this authorCarina Huber-Gries
Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Search for more papers by this authorDavid L. Kaplan
Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, 02155 USA
Search for more papers by this authorCorresponding Author
Andreas H. Teuschl
Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, 02155 USA
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Correspondence to: A.H. Teuschl; University of Applied Sciences Technikum Wien, Department of Biochemical Engineering, Wien, Austria; e-mail: [email protected]Search for more papers by this authorJohannes Zipperle
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology/AUVA Research Center, Vienna, Austria
Search for more papers by this authorCarina Huber-Gries
Department of Biochemical Engineering, University of Applied Sciences Technikum Wien, Vienna, Austria
Austrian Cluster for Tissue Regeneration, Vienna, Austria
Search for more papers by this authorDavid L. Kaplan
Department of Biomedical Engineering, Tufts University, Medford, Massachusetts, 02155 USA
Search for more papers by this authorConflict of interest: No benefit of any kind will be received either directly or indirectly by the authors.
Abstract
The control of bleeding is one of the most important interventions after a traumatic injury. Hemostatic devices delivering blood clotting accelerating agents such as fibrinogen are increasingly used due to their efficacy and their ease of application. In the present study, we describe a method to incorporate the coagulant supplements fibrinogen and thrombin in silk protein sponges by mixing the coagulants with an aqueous silk solution, followed by molding, freeze-drying, and water annealing. In this combination system, we demonstrate the delivery of fibrinogen while maintaining its hemostatic potential. Concentration ratios of silk to fibrinogen of 1.0%/2.8%, 2.3%/1.5%, and 3.0%/0.8% were used. The thrombin-induced fibrin polymeric network filled the space in and next to the silk spongy structure but also remained interconnected to the silk, providing an intact network. The mechanical characterization of the fibrinogen-releasing silk sponges before and after the induction of the fibrinogen polymerization demonstrated that the fibrin network resulted in reduced permanent deformation from 21.1% to 6.5%, 19.6% to 5.7%, and 12.7% to 9.4% for the 2.8%, 1.5%, and 0.8% fibrinogen-containing silk sponges, respectively. Moreover, the fibrin formation lead to a more linear elastic behavior over longer strain ranges. In combination, the Calcein-AM/PI staining and MTT assay results indicate uniform cell adhesion on the surface and cytocompatibility of the silk/fibrin sponges, respectively. Moreover, the co-delivery of thrombin with fibrinogen via silk as carrier material is described, offering a more mechanically robust and durable system while preserving hemostatic features of the coagulant substances for the generation of hemostatic devices. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 687–696, 2017.
REFERENCES
- 1Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Hemost 2001; 85: 958–965.
- 2Ed Rainger G, Chimen M, Harrison MJ, Yates CM, Harrison P, Watson SP, Lordkipanidzé M, Nash GB. The role of platelets in the recruitment of leukocytes during vascular disease. Platelets 2015; 26: 507–520.
- 3Curry N, Hopewell S, Dorée C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hemorrhage: A systematic review of randomized controlled trials. Crit Care 2011; 15: R92.
- 4Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: A primary hemostatic target for the management of acquired bleeding. Anesth Analg 2012; 114: 261–274.
- 5Sørensen B, Larsen OH, Rea CJ, Tang M, Foley JH, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. Semin Thromb Hemost 2012; 38: 268–273.
- 6Pourshahrestani S, Zeimaran E, Djordjevic I, Kadri NA, Towler MR. Inorganic hemostats: The state-of-the-art and recent advances. Mater Sci Eng C Mater Biol Appl 2016; 58: 1255–1268.
- 7Politi L, Aprile A, Paganelli C, Amato A, Zoccai GB, Sgura F, Monopoli D, Rossi R, Modena MG, Sangiorgi GM. Randomized clinical trial on short-time compression with Kaolin-filled pad: A new strategy to avoid early bleeding and subacute radial artery occlusion after percutaneous coronary intervention. J Interv Cardiol 2011; 24: 65–72.
- 8Schöchl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care 2010; 14: R55.
- 9Grottke O, Braunschweig T, Henzler D, Coburn M, Tolba R, Rossaint R. Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care 2010; 14: R62.
- 10Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, Hess JR, Dubick MA, Simon CD, Beekley AC, Wolf SE, Wade CE, Holcomb JB. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma 2008; 64: S79–S85; discussion S85.
- 11Weiss G, Lison S, Glaser M, Herberger S, Johanning K, Strasser T, Huber T, Spannagl M, Heindl B. Observational study of fibrinogen concentrate in massive hemorrhage: Evaluation of a Multicenter Register. Blood Coagul Fibrinolysis 2011; 22: 727–734.
- 12Dzik WH, Blajchman MA, Fergusson D, Hameed M, Henry B, Kirkpatrick AW, Korogyi T, Logsetty S, Skeate RC, Stanworth S, MacAdams C, Muirhead B. Clinical review: Canadian National Advisory Committee on Blood and Blood Products–Massive transfusion consensus conference 2011: report of the panel. Crit Care 2011; 15: 242.
- 13Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernández-Mondéjar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent J-L, Rossaint R. Management of bleeding and coagulopathy following major trauma: An updated European guideline. Crit Care 2013; 17: R76.
- 14Karlsson M, Ternström L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: A prospective observational study. Transfusion 2008; 48: 2152–2158.
- 15Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G, Sørensen B, Hagl C, Pichlmaier M. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: A randomized, placebo-controlled trial. Anesthesiology 2013; 118: 40–50.
- 16Mooney E, Loh C, Pu LLQ, ASPS/PSEF Technology Assessment Committee. The use of fibrin glue in plastic surgery. Plast Reconstr Surg 2009; 124: 989–992.
- 17Berrevoet F, de Hemptinne B. Use of topical hemostatic agents during liver resection. Dig Surg 2007; 24: 288–293.
- 18Mandell SP, Gibran NS. Fibrin sealants: Surgical hemostat, sealant and adhesive. Expert Opin Biol Ther 2014; 14: 821–830.
- 19Spotnitz WD. Fibrin sealant: Past, present, and future: A brief review. World J Surg 2010; 34: 632–634.
- 20Grimm C, Polterauer S, Helmy S, Cibula D, Zikan M, Reinthaller A, Tempfer C. A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. BMC Cancer 2014; 14: 635.
- 21Kakaei F, Seyyed Sadeghi MS, Sanei B, Hashemzadeh S, Habibzadeh A. A randomized clinical trial comparing the effect of different hemostatic agents for hemostasis of the liver after hepatic resection. HPB Surg 2013; 2013: 587608.
- 22Rousou JA. Use of fibrin sealants in cardiovascular surgery: A systematic review. J Card Surg 2013; 28: 238–247.
- 23Rickenbacher A, Breitenstein S, Lesurtel M, Frilling A. Efficacy of TachoSil a fibrin-based hemostat in different fields of surgery–a systematic review. Expert Opin Biol Ther 2009; 9: 897–907.
- 24Corral M, Ferko N, Hollmann S, Hogan A, Jamous N, Batiller J, Shen J. Clinician reported ease of use for a novel fibrin sealant patch for hemostasis: Results from four randomized controlled trials. Curr Med Res Opin 2016; 32: 367–375.
- 25Koea J, Baldwin P, Shen J, Patel B, Batiller J, Arnaud A, Hart J, Hammond J, Fischer C, James Garden O. Safety and hemostatic effectiveness of the fibrin pad for severe soft-tissue bleeding during abdominal, retroperitoneal, pelvic, and thoracic (non-cardiac) surgery: A randomized, controlled, superiority trial. World J Surg 2015; 39: 2663–2669.
- 26Clemens MW, Downey S, Agullo F, Lehfeldt MR, Kind GM, Palladino H, Marshall D, Jewell ML, Mathur AB, Bengtson BP. Clinical application of a silk fibroin protein biologic scaffold for abdominal wall fascial reinforcement. Plast Reconstr Surg Glob Open 2014; 2: e246.
- 27Bengtson B, Baxter RA, Clemens MW, Bates D. A 12-month survey of early use and surgeon satisfaction with a new highly purified silk matrix: SERI surgical scaffold. Plast Reconstr Surgery Glob Open 2014; 2: e182.
- 28Fine NA, Lehfeldt M, Gross JE, Downey S, Kind GM, Duda G, Kulber D, Horan R, Ippolito J, Jewell M. SERI surgical scaffold, prospective clinical trial of a silk-derived biological scaffold in two-stage breast reconstruction: 1-Year data. Plast Reconstr Surg 2015; 135: 339–351.
- 29Gross JE. Use of SERI surgical scaffold for soft-tissue support in a massive weight loss patient. Plast Reconstr Surgery Glob Open 2013; 1: e86.
- 30Kornstein A. SERI surgical scaffold as an adjunct for circumferential abdominoplasty and lower body lift. Plast Reconstr Surgery Glob Open 2014; 2: e244.
- 31Rockwood DN, Preda RC, Yücel T, Wang X, Lovett ML, Kaplan DL. Materials fabrication from Bombyx mori silk fibroin. Nat Protoc 2011; 6: 1612–1631.
- 32Nazarov R, Jin HJ, Kaplan DL. Porous 3-D scaffolds from regenerated silk fibroin. Biomacromolecules 2004; 5: 718–726.
- 33Corporation BH, Package insert Tachosil® Fibrin Sealant Patch. 2015.
- 34Johnson J, Package Insert EVARREST®. 2015.
- 35Jin H-J, Park J, Karageorgiou V, Kim U-J, Valluzzi R, Cebe P, Kaplan DL. Water-stable silk films with reduced β-sheet content. Adv Funct Mater 2005; 15: 1241–1247.
- 36Hu X, Shmelev K, Sun L, Gil E-S, Park S-H, Cebe P, Kaplan DL. Regulation of silk material structure by temperature-controlled water vapor annealing. Biomacromolecules 2011; 12: 1686–1696.
- 37Gruen RL, Brohi K, Schreiber M, Balogh ZJ, Pitt V, Narayan M, Maier RV. Hemorrhage control in severely injured patients. Lancet 2012; 380: 1099–1108.
- 38Granville-Chapman J, Jacobs N, Midwinter MJ. Pre-hospital hemostatic dressings: A systematic review. Injury 2011; 42: 447–459.
- 39Kheirabadi BS, Acheson EM, Deguzman R, Crissey JM, Delgado AV, Estep SJ, Holcomb JB. The potential utility of fibrin sealant dressing in repair of vascular injury in swine. J Trauma 2007; 62: 94–103.
- 40Larson MJ, Bowersox JC, Lim RC, Hess JR. Efficacy of a fibrin hemostatic bandage in controlling hemorrhage from experimental arterial injuries. Arch Surg 1995; 130: 420–422.
- 41Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel H-W, Goebell P, Schmeller N, Oberneder R, Stolzenburg J-U, Becker H, Lüftenegger W, Tetens V, Van Poppel H. Efficacy and safety of TachoSil as hemostatic treatment versus standard suturing in kidney tumour resection: A randomised prospective study. Eur Urol 2007; 52: 1156–1163.
- 42Joseph T, Adeosun A, Paes T, Bahal V. Randomised controlled trial to evaluate the efficacy of TachoComb H patches in controlling PTFE suture-hole bleeding. Eur J Vasc Endovasc Surg 2004; 27: 549–552.
- 43Cornum R, Bell J, Gresham V, Brinkley W, Beall D, MacPhee M. Intraoperative use of the absorbable fibrin adhesive bandage: Long term effects. J Urol 1999; 162: 1817–1820.
- 44Kheirabadi BS, Scherer MR, Estep JS, Dubick MA, Holcomb JB. Determination of efficacy of new hemostatic dressings in a model of extremity arterial hemorrhage in swine. J Trauma 2009; 67:450-9-60.
- 45Kundu B, Rajkhowa R, Kundu SC, Wang X. Silk fibroin biomaterials for tissue regenerations. Adv Drug Deliv Rev 2013; 65: 457–470.
- 46Vepari C, Kaplan DL. Silk as a biomaterial. Prog Polym Sci 2007; 32: 991–1007.
- 47MacIntosh AC, Kearns VR, Crawford A, Hatton PV. Skeletal tissue engineering using silk biomaterials. J Tissue Eng Regen Med 2008; 2: 71–80.
- 48Teuschl A, Heimel P, Nürnberger S, van Griensven M, Redl H, Nau T. A novel silk fiber-based scaffold for regeneration of the anterior cruciate ligament: Histological results from a study in sheep. Am J Sports Med 2016; 44: 1547–1557.
- 49Lei C, Zhu H, Li J, Feng X, Chen J. Preparation and hemostatic property of low molecular weight silk fibroin. J Biomater Sci Polym Ed 2016; 27: 403–418.
- 50Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54: 1127–1130.
- 51MacLeod JBA, Lynn M, McKenney MG, Cohn SM, Murtha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55: 39–44.
- 52Hess JR, Brohi K, Dutton RP, Hauser CJ, Holcomb JB, Kluger Y, Mackway-Jones K, Parr MJ, Rizoli SB, Yukioka T, Hoyt DB, Bouillon B. The coagulopathy of trauma: A review of mechanisms. J Trauma 2008; 65: 748–754.
- 53Deras P, Villiet M, Manzanera J, Latry P, Schved J-F, Capdevila X, Charbit J. Early coagulopathy at hospital admission predicts initial or delayed fibrinogen deficit in severe trauma patients. J Trauma Acute Care Surg 2014; 77: 433–440.
- 54Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131–142.
- 55Dunbar NM, Chandler WL. Thrombin generation in trauma patients. Transfusion 2009; 49: 2652–2660.
- 56Solomon C, Traintinger S, Ziegler B, Hanke A, Rahe-Meyer N, Voelckel W, Schöchl H. Platelet function following trauma. A multiple electrode aggregometry study. Thromb Hemost 2011; 106: 322–330.
- 57Ramsey MT, Fabian TC, Shahan CP, Sharpe JP, Mabry SE, Weinberg JA, Croce MA, Jennings LK. A prospective study of platelet function in trauma patients. J Trauma Acute Care Surg 2016; 80: 726–733.
- 58Saran K, Shi P, Ranjan S, Goh JCH, Zhang Y. A moldable putty containing silk fibroin yolk shell particles for improved hemostasis and bone repair. Adv Healthc Mater 2015; 4: 432–445.